ABP-745
Phase 2Small molecule
ABP-745 is one of 35 small molecule programs targeting Atherosclerosis. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
165 competitors in Atherosclerosis
#DrugCompanyPhaseTrials
1Avandia
Alnylam PharmaceuticalsPhase 3
Estrace
Novo NordiskPhase 3
Depo-Provera
PfizerPhase 3
Colcrys
Alnylam PharmaceuticalsPhase 3
Glucotrol
PfizerPhase 3
Actemra
RochePhase 3
Brilinta
AstraZenecaPhase 3
Ilaris
NovartisPhase 3
Benicar
CCosette Pharmaceuticals, Inc.
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atherosclerosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABP-745. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAtom Therapeutics Co., Ltd